English 
Italian Raccomandazioni ad interim di SIBioC per l’analisi sierologica dell’infezione da SARS-CoV-2
Ad interim SIBioC recommendations for serological assessment of SARS-CoV-2 infection
AUTORI
1Sezione di Biochimica Clinica e UOC Laboratorio Analisi, Università degli Studi di Verona e Azienda Ospedaliera Universitaria Integrata di Verona
2Dipartimento di Medicina Sperimentale, Università di Tor Vergata-Roma
3Istituto di Biochimica Clinica, Medicina Molecolare Clinica e Medicina di Laboratorio, Dipartimento di Biomedicina, Neuroscienze e Diagnostica Avanzata, Università degli Studi di Palermo e Dipartimento e UOC di Medicina di Laboratorio, Azienda Ospedaliera Universitaria Policlinico “P. Giaccone”, Palermo
4Dipartimento di Medicina di Laboratorio e Anatomia Patologica, Azienda Ausl e Azienda Ospedaliera Universitaria di Modena
5Dipartimento DIDAS Servizi di Diagnostica Integrata, UOC Medicina di Laboratorio, Azienda Ospedale-Università di Padova
ABSTRACT
Ad interim SIBioC recommendations for serological assessment of SARS-CoV-2 infection
The recent pandemic outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated with the pathology called COVID-19 (coronavirus disease 2019), has now become one of the most strenuous health care challenges since the emergence of the three pandemics caused by influenza viruses during the past century. Throughout the clinical decision-making of COVID-19, laboratory tests are essential for supporting the screening, diagnosis, prognostication and therapeutic monitoring of this severe infectious disease. Serological testing, that reflects the humoral immune response developing after interaction between the host and the virus (or its components), enables to garner a vast array of clinical information which can be especially used in seroprevalence or seroconversion studies. To this end, the Task Force on COVID-19 of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) has endorsed a series of technical, practical and clinical ad interim recommendations, aimed at facilitating and optimizing the introduction, clinical usage and governance of SARS-CoV-2 serological immunoassays in routine practice.